In this research from Cornell, mAbs bioconjugates are observed by the targeted delivery of small molecules, proteins, nucleic acids and more through expressions. By continuing to improve the consistency of conjugation, ADCs can increase its efficacy towards the targeted cells and tolerability. They have found two of their expression platforms to be able to generate enough antibody within a certain cell density without a need for a large surface area. Without knowing the protein sequence, the method is to be able to create antibodies, which can be used to express and discover new antibodies. Even though site-specific modification methods can be difficult to implement, they can also create more homogeneous conjugates. The targeting capabilities of mAbs can be combined with antibody-drug conjugates (ADC) to increase the cytotoxic drugs’ ability to kill cancer. ADCs are comparably a new category of antibody-based drugs emerged with chemical linkers to improve their effectiveness, and they are an example of another mechanism of how antibodies can potentially kill cancer cells.